Neurogene Inc. NGNE
Biotechnology: Pharmaceutical Preparations · IPO 2014 · data as of November 13, 2026
Neurogene Inc. (NGNE) is a healthcare company listed in the US with a market value of about $495M.
Its overall Stock Analiz score is 0.6 out of 5 (weak). The strongest part is financial health (2/5); the weakest is value (0/5).
Key numbers: a 5-year average ROIC of -28%.
About Neurogene
Neurogene is listed in the US and classified in biotechnology: pharmaceutical preparations, IPO year 2014. Revenue went from $25M in 2018 to $925000 in 2024, a decline of about 42.3% a year. It was profitable in 0 of the last 10 years in our data. Its share count fell by 61% over three years (buybacks).
Score: 0.6 / 5
Checks passed
- More cash than debt, or low debt to equity
- Liabilities below 60% of assets
- Share count down over 3 years (buybacks)
Checks not passed
- P/E below 25
- P/E below the industry median
- P/FCF below 20
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- Revenue growth above 10% last year
- 3-year revenue growth above 10% a year
- Profit margin improving
Valuation
Growth and quality
Financials, last 10 years
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $925000 | $0 | — | — | — | — | $25M | — | — |
| Net income | -$90M | -$75M | -$36M | -$55M | -$61M | -$33M | -$69M | -$32M | -$50M | -$37M |
| Free cash flow | -$78M | -$71M | -$52M | -$55M | -$51M | -$27M | -$16M | -$32M | -$45M | -$31M |
| EPS (diluted) | $-4.24 | $-4.28 | — | $-1.04 | $-1.10 | $-0.64 | $-2.57 | $-1.34 | $-2.14 | $-1.96 |
| Net margin | — | -8123.7% | — | — | — | — | — | -126.3% | — | — |
| ROIC | -37.6% | -25.6% | -21.9% | — | — | -13.1% | -39.3% | -35.5% | -40.8% | -26.0% |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
What analysts expect
The average 12-month price target from 8 analysts is $77.62, 224% above the current price; targets range from $46.00 to $166.00; the consensus rating is “Strong buy”; expected EPS is $-5.00 for the fiscal year ending December 31, 2026.
Frequently asked questions
Does Neurogene pay a dividend?
Not currently.
Is Neurogene a good stock to buy?
We do not give buy or sell advice. Neurogene scores 0.6 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.